

# Reassessing Bioavailability of Silymarin

Shamama Javed, PhD; Kanchan Kohli; Mushir Ali

## Abstract

Silymarin, a flavanolignan derived from *Silybum marianum*, possesses diverse pharmacological activities, including hepatoprotective, antioxidant, anti-inflammatory, anticancer, and cardioprotective. Although clinical trials have shown silymarin is safe at high doses (>1500 mg/day) in humans, the pharmacokinetic studies over the past three decades related to absorption, distribution, metabolism, and excretion of silymarin have revealed poor absorption, rapid metabolism, and ultimately poor oral bioavailability. For optimum silymarin bioavailability, issues of solubility, permeability, metabolism, and excretion must be addressed. An array of methods have been described in recent years that can improve its bioavailability, including complexation with  $\beta$ -cyclodextrins, solid dispersion method, formation of microparticles and nanoparticles, self-microemulsifying drug delivery systems, micelles, liposomes, and phytosomes. This article critically reviews the recent published literature on various techniques for increasing the bioavailability of silymarin.

(*Altern Med Rev* 2011;16(3):239-249)

## Introduction

*Silybum marianum*, commonly known as milk thistle in the family Asteraceae, is one of the oldest and thoroughly researched plants of ancient times for the treatment of liver and gallbladder disorders, including hepatitis, cirrhosis, jaundice, and protection against *Amanita phalloides* mushroom and other toxin poisonings.<sup>1</sup> Silymarin, the active component of this plant, is a standardized extract consisting of approximately 70- to 80-percent silymarin flavanolignans (silybin A & B, isosilybin A & B, silydianin, and silychristin) and flavonoids (taxifolin and quercetin), and the remaining 20-30 percent consisting of a chemically undefined fraction comprised of polymeric and oxidized polyphenolic compounds (Figure 1).<sup>2</sup>

Silymarin possesses a wide range of biological and pharmacological effects, including antioxidant activity,<sup>3</sup> stimulation of protein synthesis and cell regeneration (making it useful in the treatment of toxic liver damage, chronic inflammatory liver diseases, and liver cirrhosis),<sup>4,5</sup> and impressive anticancer effects against several human carcinoma cell lines.<sup>6,7</sup> In addition, antidiabetic activity,<sup>8</sup> cardioprotection,<sup>9</sup> anti-inflammatory, antifibrotic, hypolipidemic, neurotrophic, neuroprotective, and immune modulation effects are well documented.<sup>10</sup>

## Physicochemical and Pharmacokinetic Properties of Silymarin

### Dosage

All clinical trials of milk thistle conducted in the past have demonstrated safety and efficacy of silymarin at doses of 1,200-1,500 mg/day.<sup>1</sup> The typical oral adult dose of silymarin is 240-800 mg/day in two or three divided doses.<sup>11</sup>

### Solubility

Low water solubility (0.04 mg/mL) of silymarin is reported. Solubility of silymarin in various other solvents like transcutool, ethanol, polysorbate 20, and glyceryl monooleate is 350.1 mg/mL, 225.2 mg/mL, 131.3 mg/mL, and 33.2 mg/mL, respectively.<sup>12</sup> Silymarin possesses no lipophilic properties, even though its water solubility is poor.<sup>12</sup>

### Bioavailability


Silybin is the primary and most active component of the silymarin complex. All pharmacokinetic parameters of silymarin are referred to, and standardized as, silybin. Orally administered silymarin (silybin) is rapidly absorbed with a  $t_{max}$  (2-4 hours) and  $t_{1/2}$  (6 hours). Only 20-50 percent of oral silymarin is absorbed from the gastrointestinal tract where it undergoes extensive enterohepatic circulation. Therefore, absorption of silymarin from the gastrointestinal tract is low, making

Shamama Javed, PhD –  
Research Scholar,  
Department of  
Pharmaceutics, Faculty of  
Pharmacy, Jamia Hamdard,  
New Delhi, India

Kanchan Kohli – Associate  
Professor, Department of  
Pharmaceutics, Faculty of  
Pharmacy, Jamia Hamdard,  
New Delhi, India  
Correspondence address:  
Department of  
Pharmaceutics, Faculty of  
Pharmacy, Jamia Hamdard,  
New Delhi-62, India  
Email:  
kanchankohli@gmail.com

Mushir Ali – Professor,  
Department of  
Pharmaceutics, Faculty of  
Pharmacy, Jamia Hamdard,  
New Delhi, India

Figure 1. Components of Silymarin



bioavailability poor.<sup>13</sup> Wu et al reported 0.73-percent oral bioavailability of silymarin (standardized as silybin) in rat plasma.<sup>14</sup>

### Tissue Distribution

Zhao and Agarwal performed a tissue distribution experiment in mice and concluded that silybin (50 mg/kg), both in free and conjugated form (e.g., glucuronide and sulfate conjugated forms), is quickly absorbed after oral administration and has a good tissue distribution profile in various tissues examined.<sup>15</sup>

### Metabolism

Silymarin (standardized as silybin) undergoes phase I and phase II biotransformation in the liver. It is metabolized by CYP450-2C8 *in vitro* into o-demethylated silybin (major) and mono- and dihydroxy- silybin (minor) metabolites.<sup>16</sup> During phase II, multiple conjugation reactions have been observed that include the formation of silybin monoglucuronide, silybin diglucuronide, silybin monosulfate, and silybin diglucuronide sulfate (Figure 2).<sup>17</sup>

### Excretion

Silybin in humans and rats demonstrates rapid elimination of both free and conjugate forms. Wen et al, through pharmacokinetic analysis, discovered that silymarin flavonolignans were rapidly

eliminated with short half-lives (1-3 and 3-8 hours for free and conjugated forms, respectively). Studies in humans and rodents suggest that biliary excretion of glucuronide and sulfate conjugates is the major route for silymarin's elimination.<sup>18</sup>

### Summary of Causes for Limited Silymarin Bioavailability


The four major causes of limited silymarin bioavailability are extensive phase II metabolism, low permeability across intestinal epithelial cells, low aqueous solubility, and rapid excretion in bile and urine (Figure 3). These factors necessitate the incorporation of silymarin into a form that can augment its bioavailability. Table 1 illustrates the various methods used to enhance silymarin's bioavailability.

### Methods to Augment Silymarin Bioavailability Complexation with Phospholipids

From standardized silymarin, silybin can be isolated and combined on a molecular level with phosphatidylcholine. The formulation, initially named IdB 1016 (from Indena; Italy), is patented as Siliphos® and also referred to as silipide or silybin phytosome. It is provided as one part silybin and two parts phosphatidylcholine.<sup>19</sup> Major advantages include increased absorption, lower therapeutic dose, and better stability profile.<sup>20</sup>

**Keywords:** flavonolignan, flavonoid, milk thistle, solubility, pharmacokinetics, silymarin, bioavailability, silybin, silybum, phytosomes, liposomes, absorption

Figure 2. Metabolites of Silymarin



Barzaghi et al assessed the Siliphos pharmacokinetic profile in humans. Siliphos bioavailability was found to be significantly greater than that of non-complexed silymarin, probably because complexation with phosphatidylcholine facilitating its passage across the gastrointestinal mucosa.<sup>21</sup>

Morazzoni et al found silybin complexation with phosphatidylcholine was 10 times more bioavailable than silybin alone.<sup>22,23</sup>

Schandalik et al administered silipide to patients with cholestasis secondary to biliary extrahepatic obstruction. On average, the area under the curve (AUC) for total silybin was more than 40-fold greater than the AUC for free silybin.<sup>24</sup>


Skottová et al administered radio-labeled silybin and their complexes 1:1 with phosphatidylcholine concurrently with unlabeled silybin in a comparative study of bioavailability in the rat. The superior bioavailability of radio-labeled silybin was observed with increased radioactivity in liver, kidney, spleen, and heart.<sup>25</sup>

Yanyu et al compared the oral pharmacokinetic characteristics and bioavailability of silybin-phospholipid complexes to silybin-methylglucamine in rats. Pharmacokinetic parameters were found to be  $T_{max}$  10 minutes and 5 minutes;  $C_{max}$  126.72 ng/mL and 104.29 ng/mL,  $AUC_{0-\infty}$  1,020.33 ng/mL/hour and 235.81 ng/mL/hour, respectively. Silybin

bioavailability in rats increased remarkably after oral administration of silybin-phospholipid complex compared to silybin-methylglucamine, primarily due to improvement of the lipophilic property of the complex.<sup>26</sup>

Filburn et al, studying the bioavailability of a phytosome complex in dogs, found  $C_{max}$ ,  $T_{max}$ , and  $AUC_{0-24}$  values for total silybin were  $1,310 \pm 880$  ng/mL, 2.87 ± 2.23 hours, and  $11,200 \pm 6,520$  ng/mL per hour, respectively. Corresponding values for a standardized silymarin extract were  $472 \pm 383$  ng/mL, 4.75 ± 2.82 hours, and  $3,720 \pm 4,970$  ng/mL/hour, respectively, showing the phytosome complex markedly enhances bioavailability in dogs.<sup>27</sup>

Figure 3. Primary Reasons for Poor Oral Bioavailability of Silymarin



Verschoye et al advanced silipide to the stage of clinical investigation in prostate cancer.<sup>28</sup> Silipide is silybin combined with phospholipids to increase the oral bioavailability and biological activity of silybin.

### Liposomes

The aim of this technique is to engage silymarin into liposomal structures to make it more effective, safe, and targeted to liver cells. Liposomes are spherical, self-enclosed structures with a lipid bilayer (ranging from some nanometers to several micrometers) that possess a unique amphiphilic character.<sup>29</sup>

Maheshwari et al prepared liposomal vesicles of silybin by the ethanol injection method. The results of the *in vivo* studies for hepatoprotective activity in mice against carbon tetrachloride induced hepatotoxicity and gastroprotective activity using the pyloric ligation method indicated 55-percent hepatoprotection by silymarin liposomes compared to 33- and 24 percent by non-liposomal silymarin and liposomes without silymarin, respectively.<sup>30</sup> Liposomes, even without silymarin, can convey some hepatoprotective effects because of their liver supportive phospholipid content.

Xiao et al studied physicochemical properties, pharmacokinetic characteristics, and bioavailability of silymarin proliposomes in rats after oral administration. Proliposomes are defined as dry, free flowing particles that immediately form liposomal suspension on contact with water. By this technique the stability problem of liposomes can be resolved without influencing their intrinsic characteristics. The encapsulation efficiency (amount of drug that goes into the liposomal core/total amount of drug incorporated) of silymarin liposomes is up to 90 percent, with an average particle size of about 238.8 nm and achievement of good stability.<sup>31</sup>

Yanyu et al compared the pharmacokinetic characteristics and bioavailability of silymarin proliposome with pure silymarin after oral administration to beagle dogs. Pharmacokinetic parameters of silymarin proliposome and silymarin were  $T_{max}$  both 30 minutes;  $C_{max}$  472.62 and 89.78 ng/mL; and  $AUC_{0-6}$  2,606.21 and 697 ng/mL/hour, respectively. This study demonstrated the high bioavailability and enhanced gastrointestinal absorption of silymarin proliposome compared to pure silymarin.<sup>32</sup>

**Table 1. Methods of Silymarin Bioavailability Augmentation**

Conventional Methods	Novel Methods
Complexation	Controlled delivery systems
Phospholipids	Transdermal drug delivery system
$\beta$ -cyclodextrins	Sustained-release systems
Incorporation in solid dispersions	Targeted delivery systems
Formation of derivatives	Microspheres
Salts	Nanoparticles
Prodrug	Liposomes
Glycosides	Self-microemulsifying drug delivery systems
Increase in solubility profile	Polymeric micelles
Floating tablets	
Crystal engineering	
Soft gel capsule technology	
Micronization up to 5-20 microns	

El-Samaligy et al demonstrated increased bioavailability of silymarin using a buccal liposomal delivery system.<sup>33</sup> In a subsequent study, these silymarin liposomes were evaluated for hepatoprotective activity against carbon tetrachloride-induced oxidative stress in albino rats. The liposomal formulation significantly reduced serum glutamic pyruvic transaminase (SGPT) level compared to a silymarin suspension.<sup>34</sup>

Dube et al primed galactosylated liposomes for silybin delivery and targeting lectin receptors present on hepatocytes by covalently attaching them with p-aminophenyl  $\beta$ -D-galactopyranoside. A positive hepatoprotective effect demonstrated galactosylated liposomes were more effective than non-galactosylated liposomes and suitable for targeted delivery of silybin to hepatocytes.<sup>35</sup>

### Inclusion Complex with $\beta$ -Cyclodextrins

Complexation is also an approach to increase the solubility of a compound. Cyclodextrin is known to enhance solubility of a variety of compounds by forming what are called inclusion complexes.<sup>36,37</sup>

Arcari et al demonstrated a dramatic increase in dissolution rate of a silybin and  $\beta$ -cyclodextrin complex (>90% within five minutes) compared to non-complexed silybin that is almost insoluble. After administration of the silybin complex *in vivo*, the silybin concentration in rat bile was nearly 20-times greater than after administration of silybin in its traditional form.<sup>38</sup>

Voinovich et al prepared and optimized the physicochemical properties of a

silybin- $\beta$ -cyclodextrin complex by XRD, DRIFT, and Raman spectroscopy. The activated systems significantly enhanced the *in vitro* drug dissolution kinetics with subsequent improved oral bioavailability. Furthermore, *in vivo* studies on rats revealed a 6.6-fold increased bioavailability compared to *S. marianum* (Italian commercial product Silirex<sup>®</sup> 200 mg capsules).<sup>39</sup>

### Incorporation in Solid Dispersions

Solid dispersions appear to be a viable technique for overcoming the bioavailability problem of poorly water-soluble substances.<sup>40</sup> This section addresses various solid dispersion formulations of silymarin that can lead to a highly bioavailable product.

Li et al discovered that the dissolution rate of silymarin considerably increased when formulated in solid dispersion of polyethylene glycol 6000 (PEG 6,000) compared to pure silymarin; the increased dissolution rate might favorably impact oral absorption.<sup>41,42</sup>

Zhang et al formulated a water-soluble polyethylene glycol prodrug of silybin and characterized it by proton NMR, FT-IR, and TOF-MS. The drug loading capability was found to be 6.65 percent and the solubility was 800 mg/mL, indicating significantly higher solubility of the prodrug in comparison with silybin alone.<sup>43</sup>

Qiu et al prepared dripping pills of silymarin and PEG 6,000 in a 1:4 ratio by the traditional fusion method. The dissolution rates of silymarin dripping pills were higher than the rates of marketed silymarin preparations, including Yiganling film-coated tablets (China), Yiganling sugar-coated tablets (China), and Legalon capsules (Germany).<sup>44</sup>

Nakhat et al formulated silymarin- $\beta$ -cyclodextrin solid dispersion tablets by a direct compression technique using superdisintegrants such as croscarmellose sodium, sodium starch glycolate, and polyplasdone in different concentrations. All the formulations showed improved dissolution over marketed formulations, reflecting a vital role of  $\beta$ -cyclodextrin in promotion of silymarin oral bioavailability.<sup>45</sup>

Sun et al enhanced the dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets after preparation by a one-step fluid-bed coating technique, which increased the relative bioavailability of silybin solid dispersion pellets about five-fold compared to a silybin suspension, confirming enhanced oral bioavailability.<sup>46,47</sup>

### Formation of Derivatives: Salt, Prodrug, and Glycosides

Formation of water-soluble derivatives, salts, and glycosides has helped increase the bioavailability of silymarin. Glycosylation often improves the solubility of various drugs without affecting their activity. Respective glycosides may also act as prodrugs. Moreover,  $\beta$ -galactosylation can improve hepatic cell uptake, known to contain high concentrations of  $\beta$ -galactoside receptors.<sup>48</sup> A salt of silybin is available as silybin dihemisuccinate, which is given in emergency cases of *Amanita phalloides* poisoning.<sup>49,50</sup>

Pifferi et al synthesized silybin 11-*o*-phosphate-3 by selective phosphorylation of silybin with POCl<sub>3</sub>. The pharmacological activity was evaluated in the rat by using the praseodymium poisoning test. Results showed that the compound possessed hepatoprotective activity, possibly with lower potency compared to the reference drug silybin hemisuccinate.<sup>51</sup>

Kren et al isolated two silybin diastereoisomers in the form of acetylated monoglycosides. They were between four and 30 times more water soluble and their hepatoprotectivity was equal to the parent compound silybin.<sup>48</sup>

Kosina et al prepared four  $\beta$ -glycosides of silybin (silybin  $\beta$ -galactoside, silybin  $\beta$ -glucoside, silybin  $\beta$ -maltoside, silybin  $\beta$ -lactoside) in order to improve silybin water solubility and bioavailability.<sup>52,53</sup>

Gazak et al synthesized a silybin derivative (2,3-dehydrosilybin). This compound demonstrated improved water solubility by selective oxidation of the parent compound silybin. Although the antioxidative property of dehydrosilybin was superior to silybin by one order, its water solubility was too low for application in an aqueous milieu. On the other hand 2,3-dehydrosilybinic acid was found to be fairly soluble, with better anti-lipoperoxidation and other antioxidant properties than that of silybin.<sup>54</sup> Dzubak et al prepared a series of *o*-alkyl derivatives (methyl and benzyl) of silybin that demonstrated enhanced cytotoxic and p-glycoprotein modulatory activity.<sup>55</sup>

Zhang et al increased the solubility of silybin in aqueous polyvinylpyrrolidone (PVP k30) solution at the temperature range from 293.15 to 313.15 K by a solid = liquid equilibrium method. Experimental results reveal that the solubility of silybin increased with the increase both in PVP concentration and temperature.<sup>56</sup>

Bai et al increased the solubility of silybin in aqueous dextran solution and aqueous poly (ethylene glycol) 6000 solution by a solid liquid equilibrium method at temperatures ranging from 293.15 to 313.15 K. Experimental results reveal that the solubility of silybin increased in both solvents with the increase both in concentration and temperature.<sup>57,58</sup>

Bai et al increased the solubility of silybin in aqueous hydrochloric acid solution at temperatures ranging from 293.15 to 313.15 K. Experimental results also revealed that the solubility increased with the increase of both temperature and pH value.<sup>59</sup>

### Floating Tablets

Garg and Gupta formulated floating effervescent tablets of silymarin to prolong gastric time and compared the *in vitro* release profile and drug release kinetics with that of a product with the same ingredients but as floating non-effervescent tablets. The developed floating effervescent tablets of silymarin prolonged the drug release for 24 hours, thereby improving the bioavailability and patient compliance.<sup>60</sup>

### Softgel Technology

A cross-over, randomized study on silybin bioavailability in softgel capsules was conducted by Savio et al and compared to silybin in hard shell capsules. In the softgel, silybin was complexed in 1:2 ratio with phosphatidylcholine. The pharmacokinetic parameters demonstrated that the mean values of both  $C_{max}$  and  $AUC_{0-1}$  increased dramatically when the patented soft gelatin capsule formulations were administered ( $C_{max}$  more than three-fold and  $AUC_{0-1}$  more than two-fold) in comparison to pure silybin.<sup>61</sup> Since the silybin was complexed with phosphatidylcholine in the softgel but provided as straight silybin in the hard shell capsule, it is impossible to determine whether the capsule type made a significant difference.

### Micronization and Nanonization

More than 40 percent of compounds identified through combination screening programs are poorly water soluble. These molecules are difficult to formulate using conventional approaches and are associated with innumerable formulation-related performance issues. Micronization and nanonization are newer techniques for increasing drug bioavailability. Micronization is the process of reducing the particle size of a solid to 2-5  $\mu\text{m}$ ;

whereas, in nanonization, particle size is reduced to 5-300 nm to increase its surface area, leading to an improvement in the dissolution rate.<sup>62</sup>

Di Piero et al reported on the clinical efficacy, safety, and tolerability of micronized silymarin as BIO-C<sup>®</sup>. Used as a galactagogue, consumption resulted in an 85-percent increase in daily breast milk production in healthy women after delivery, without affecting milk quality.<sup>63</sup> Similarly, Capasso et al evaluated the effect of a micronized standardized extract of *S. marianum* on serum levels of prolactin in female rats. A 14-day treatment with silymarin (25-200 mg/kg, given orally) increased serum prolactin levels in a dose-dependent manner due to increased bioavailability.<sup>64</sup>

Zhang et al effectively prepared micronized silybin particles by an emulsion solvent diffusion method using sodium dodecyl sulfate concentration (0.1 wt %) at 30°C and 15°C. Dissolution tests demonstrated that micronized silybin exhibited a significantly enhanced dissolution rate when compared to commercial, non-micronized silybin powder.<sup>65</sup>

### Controlled Delivery Systems Transdermal Delivery Systems

Delivery of silymarin via the skin has, until recently, been virtually unexplored. In 2010, Hung et al studied the transdermal absorption of silymarin components (silybin, silydianin, and silychristin) and concluded that the lipophilicity increased in the order of silychristin < silydianin < silybin. Greater lipophilicity conferred higher skin deposition, but had a minor effect on permeation across the skin in the less-ionized form (pH 8). It is apparent that compounds in the less-ionized form showed higher skin uptake compared to the more-ionized form.<sup>66</sup>

### Sustained Release Systems

Sustained delivery systems for herbal medicines are difficult because of their complex composition. Lu et al generalized the concept of synchronized release of silymarin from erodible matrix systems based on glyceryl monostearate and polyethylene glycol 6000 or poloxamer 188 by a melt fusion method to perform strict control on synchronized release of the five active components of silymarin (i.e., taxifolin, silychristin, silydianin, isosilybin, and silybin). The release was sustained up to 12 hours with erosion-controlled release mechanisms.<sup>67</sup>

## Targeted Delivery Systems Microspheres

Abrol et al formulated silymarin-loaded lipid microspheres with constituents, including an internal oily core, a surfactant such as soybean lecithin, and cosurfactants such as span 20 (sorbitan laurate), tween 20 (polyoxyethylene 20 sorbitan monolaurate), tween 80 (polyoxyethylene 80 sorbitan monooleate), and propylene glycol in different concentrations to optimize the final formulation for globule size range, structural integrity, sustainability, and percent drug-holding capacity. When compared to a silymarin solution in propylene glycol, the mean percent release from silymarin-loaded lipid microspheres was 56 percent after 36 hours, compared to 18 percent with the silymarin solution.<sup>68,69</sup>

## Nanocarriers

Nanocarriers, such as nanoparticles, niosomes, solid lipid nanoparticles, polymeric micelles, and dendrimers, are colloidal particulate systems with a size range of 10-1,000 nm. They have been successfully utilized in the diagnosis, treatment, and monitoring of various diseases because of their bioavailability-enhancing ability.<sup>70</sup>

Ibrahim et al prepared and characterized sodium alginate-based, pH-responsive, hydrogel microspheres encapsulating poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles. This preparation technique is ideal for encapsulation of hydrophobic ingredients such as silymarin. Also, the encapsulation of the water-insoluble silymarin into nano-sized particles would enhance the dissolution and consequently the bioavailability of silymarin.<sup>71</sup>

Parveen et al prepared a nanocarrier formulation of silymarin to increase its oral bioavailability. The pharmacokinetic parameters AUC and  $C_{max}$  of nanoemulsion after oral administration were four-fold and six-fold higher than those of a silymarin drug suspension.<sup>72</sup>

Jun et al prepared silymarin-solid lipid nanoparticles (SLNs) by lyophilization and investigated the effect of particle size on oral absorption of various sized nanoparticles (150 nm, 500 nm, and 1,000 nm). The oral bioavailability of 150-nm SLNs in rats was significantly higher than the other two SLN sizes (AUC of 150 nm was 2.08-fold and 2.54-fold that of 500-nm and 1,000-nm SLNs, respectively).<sup>73</sup> In a body distribution study of silymarin-SLNs after oral administration, the relative bioavailability was 2.79-fold higher compared to the silymarin suspension (milled silymarin powder). These results indicated

preparing silymarin as SLNs can improve the oral bioavailability.<sup>74</sup>

Xu et al formulated silybin lipid nanoparticles by a thin film emulsion high pressure homogenization technique and studied the biodistribution in mice. This method resulted in increased distribution of silybin in blood and liver compared with the preparations on the market. The drug targeting index (DTI; Drug Targeting Index =  $[AUC_{liver} / AUC_{blood}]_{SLN} / (AUC_{liver} / AUC_{blood})_{Market\ preparation}$ ) in the liver was 1.81, leading the authors to conclude that SLN can increase the uptake of silybin in liver after oral administration, which could be of benefit in the treatment of hepatitis.<sup>75</sup> Note: The DTI was calculated based on AUC at a target (liver) and systemic site (venous blood) following administration into and sampling from both sites. The closer a compound's DTI is to 1, the less targeting effect it has. The liver DTI of SLN compared to the market preparation was 1.81, indicating that SLN was more effective than the market preparation in liver targeting.<sup>76,77</sup>

Zhang et al developed stealth solid lipid nanoparticles (size in the nanometer range) for silybin. Stearic acid was used as a biodegradable lipid and Brij-78 as surfactant. A very slow release of silybin was reported from SLNs.<sup>78</sup>

Jia et al prepared silybin-loaded nanostructured lipid carriers (NLC) with various liquid lipid contents by the method of emulsion evaporation at a high temperature and solidification at a low temperature. The size and morphology of nanoparticles were significantly influenced by the liquid lipid content. Compared with solid lipid nanoparticles, NLC provided improved drug-loading capacity that increased with increasing liquid lipid content. The drug *in vitro* release behavior from NLC displayed a biphasic pattern with burst release at the initial stage and prolonged release afterwards; successful controlled release rate was achieved by controlling the liquid lipid content.<sup>79</sup>

## Self Micro-Emulsifying Drug Delivery Systems (SMEDDS)

SMEDDS are isotropic mixtures of oils, surfactants, and/or co-solvents used in the oral delivery of poorly water-soluble drugs. They improve oral bioavailability via enhancement of gastrointestinal solubilization. Other advantages are potential reduction in dose, selective targeting of the substance toward specific absorption windows in the gastrointestinal tract, and protection of the substance from a hostile gut environment like acids and enzymatic degradation.<sup>80</sup>

Yuan et al investigated the absorption of silymarin microemulsion in rat intestine and found it to be well absorbed at the middle and lower segments of the intestine. The absorption was a first-order process with a passive diffusion mechanism.<sup>81</sup>

Relative bioavailability of silymarin was dramatically enhanced an average of 1.88- and 48.82-fold that of silymarin-polyethylene glycol 400 solution and suspension, respectively, concluding enhanced bioavailability of silymarin by SMEDDS.<sup>82</sup>

Woo et al formulated SMEDDS of silymarin, and upon its oral administration to rats the bioavailability of the drug from the SMEDDS was found to be 3.6-times higher than the reference dosage form (i.e., Legalon capsules).<sup>12</sup>

### Polymeric Micelles

Polymeric micelles are nano-sized particles composed of polymer and copolymer chains. They wrap a hydrophobic substance into their hydrophobic cores and significantly increase drug delivery by preventing its degradation by the body. They can survive reticuloendothelial system identification and capture because the polymer is non-toxic, biocompatible, and non-immunogenic. This extends its retention time and improves its bioavailability.

Wu et al prepared silymarin-loaded amphiphilic chitosan micelles and performed an *in situ* silymarin absorption investigation in rat intestine. The absorption of silymarin micelles at different segments of rat intestine was significantly higher

**Table 2. Summary of Techniques for Enhancement of Silymarin Bioavailability**

Bioavailability Augmentation Methods	Improvement in Bioavailability	Reference
Complexation with phospholipids	Siliphos 10 times more bioavailable than silybin alone	Morazzoni P et al; 1992; 1993
Inclusion complexes with $\beta$ -cyclodextrins	Silybin cyclodextrin complex 20 times more bioavailable than silybin alone	Arcari M et al; 1992
Incorporation in solid dispersions	Solid dispersion form of silybin is five-fold more bioavailable than the silybin suspension	Sun N, Wei X et al; 2008
Glycoside formation	Silybin glycosides 4-30 times more water-soluble than pure silybin	Kren V et al; 1997
Floating tablets	Prolonged the drug release for 24h, thereby improving the bioavailability	Garg R, Gupta GD; 2009
Soft gel capsule technology	Increase in Cmax more than three-fold and AUC <sub>0-1</sub> more than two-fold	Savio D et al; 1998
Controlled drug delivery systems	Prolonged and sustained release is achieved	Lu C et al; 2007
Microspheres	The mean percent release of $56.70 \pm 2.03\%$ was observed in 36 h from silymarin microspheres, compared to $18.67 \pm 0.192\%$ with silymarin solution	Abrol S et al; 2004
Nanoparticles	The relative bioavailability was 2.79-fold higher compared to the silymarin suspension	Jun H et al; 2007
Liposomes	Tmax, Cmax and AUC <sub>0-<math>\infty</math></sub> of silymarin liposome in beagle dogs were much higher than pure silymarin, concluding high bioavailability profile	Yanyu X et al; 2006
Self microemulsifying drug delivery systems (SMEDDS)	Upon oral administration in rats the bioavailability of silymarin from the SMEDDS was found 3.6-fold higher than the Legalon capsules	Woo JS et al; 2007

Liu et al developed SMEDDS of silymarin and compared them with commercial capsules (Legalon, Germany) and tablets (Yiganling, China). The SMEDDS formulation proved to be a suitable alternative for improving the oral absorption of silymarin.<sup>83</sup>

than that of silymarin suspension.<sup>84</sup>

Li et al found micelles significantly increased the amount of silybin in the liver.<sup>85</sup>

A summary of the techniques to enhance silymarin bioavailability is found in Table 2.

## Future Directions

Although milk thistle demonstrates significant clinical efficacy, its utility is limited by poor oral bioavailability. A number of approaches for increasing the oral bioavailability of silymarin have been extensively studied, including solubilization, cosolvency, complexation with  $\beta$ -cyclodextrins, and solid dispersion. More targeted delivery systems are currently being explored – a transdermal delivery of silymarin for various skin-related disorders like skin cancers, for example. Another possible approach to improve bioavailability is to reduce the particle to nano size by methods like pearl milling, high pressure homogenization, emulsification, and precipitation, which can lead to superior *in vivo* drug performance.

## Acknowledgements

S. Javed wishes to thank the Indian Council of Medical Research (ICMR), New Delhi, India, for providing financial assistance for the Senior Research Fellowship (SRF). The authors also wish to thank the Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard University, New Delhi, for providing scientific support.

## References

- Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. *Indian J Med Res* 2006;124:491-504.
- Kren V, Walterova D. Silybin and silymarin – new effects and applications. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2005;149:29-41.
- Koksals E, Gulcin I, Beyza S, et al. *In vitro* antioxidant activity of silymarin. *J Enzyme Inhib Med Chem* 2009;24:395-405.
- Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. *Clin Drug Investig* 2002;22:51-65.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. *Drugs* 2001;61:2035-2063.
- Singh RP, Aggarwal R. Prostate cancer prevention by silibinin. *Curr Cancer Drug Targets* 2004;4:1-11.
- Yang SH, Lin JK, Chen WS, Chiu JH. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. *J Surg Res* 2003;113:133-138.
- Lirussi F, Beccarello A, Zanette G, et al. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. *Diabetes Nutr Metab* 2002;15:222-231.
- Rao PR, Viswanath RK. Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. *Exp Clin Cardiol* 2007;12:179-187.
- Radko L, Cybulski W. Application of silymarin in human and animal medicine. *J Preclin Clin Res* 2007;1:22-26.
- Dixit N, Baboota S, Kohli K, et al. Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. *Indian J Pharmacol* 2008;39:172-179.
- Woo JS, Kim TS, Park JH, Chi SC. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. *Arch Pharm Res* 2007;30:82-89.
- Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. *J Ethnopharmacol* 2009;121:185-193.
- Wu JW, Lin LC, Hung SC, et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. *J Pharm Biomed Anal* 2007;45:635-641.
- Zhao J, Aggarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. *Carcinogenesis* 1999;20:2101-2108.
- Jancova P, Anzenbacherova E, Papouskova B, et al. Silybin is metabolized by cytochrome P450 2C8 *in vitro*. *Drug Metab Dispos* 2007;35:2035-2039.
- Wu JW, Lin LC, Hung SC, et al. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. *Drug Metab Dispos* 2008;36:589-596.
- Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profiles of free, conjugated and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. *Drug Metab Dispos* 2008;36:65-72.
- Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). *Altern Med Rev* 2005;10:193-203.
- Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea and grape seed extracts. *Altern Med Rev* 2009;14:226-246.
- Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on Idb 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. *Eur J Drug Metab Pharmacokinet* 1990;15:333-338.
- Morazzoni P, Magistretti MJ, Giachetti C, Zanol G. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats. *Eur J Drug Metab Pharmacokinet* 1992;17:39-44.

23. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. *Eur J Drug Metab Pharmacokinet* 1993;18:289-297.
24. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. *Arzneimittelforschung* 1992;42:964-968.
25. Skottová N, SVagera Z, Vecera R, et al. Pharmacokinetic study of iodine-labeled silibinins in rat. *Pharmacol Res* 2001;44:247-253.
26. Yanyu X, Yunmei S, Zhipeng C, Quieng P. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. *Int J Pharm* 2006;307:77-82.
27. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. *J Vet Pharmacol Ther* 2007;30:132-138.
28. Verschoyle RD, Greaves P, Patel K, et al. Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. *Eur J Cancer* 2008;44:898-906.
29. Fang JY. Nano- or submicron-sized liposomes as carriers for drug delivery. *Chang Gung Med J* 2006;29:358-362.
30. Maheshwari H, Aggarwal R, Patil C, Katare OP. Preparation and pharmacological evaluation of silibinin liposomes. *Arzneimittelforschung* 2003;53:420-427.
31. Xiao YY, Song YM, Chen ZP, Ping QN. Preparation of silymarin proliposomes and its pharmacokinetics in rats. *Yao Xue Xue Bao* 2005;40:758-763. [Article in Chinese]
32. Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. *Int J Pharm* 2006;319:162-168.
33. El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. *Int J Pharm* 2006;308:140-148.
34. El-Samaligy MS, Afifi NN, Mahmoud EA. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and *in vivo* performance. *Int J Pharm* 2006;319:121-129.
35. Dube D, Khatri K, Goyal AK, et al. Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin. *Drug Dev Ind Pharm* 2010;36:547-555.
36. Chaubal MV. Application of drug delivery technologies in lead candidate selection and optimization. *Drug Discov Today* 2004;9:603-609.
37. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. *J Control Release* 2007;123:78-99.
38. Arcari M, Brambilla A, Brandt A, et al. A new inclusion complex of silibinin and beta-cyclodextrins: *in vitro* dissolution kinetics and *in vivo* absorption in comparison with traditional formulations. *Boll Chim Farm* 1992;131:205-209. [Article in Italian]
39. Voinovich D, Perissutti B, Grassi M, et al. Solid state mechanochemical activation of *Silybum marianum* dry extract with betacyclodextrins: characterization and bioavailability of the coground systems. *J Pharm Sci* 2009;98:4119-4129.
40. Sethia S, Squillante E. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. *Crit Rev Ther Drug Carrier Syst* 2003;20:215-247.
41. Li FQ, Hu JH, Wang H, et al. Relativities between lattice changes and the function of dissolution improvement of poorly soluble drug silymarin based upon PEG 6,000 solid dispersion system. *Yao Xue Xue Bao* 2002;37:294-298. [Article in Chinese]
42. Li FQ, Hu JH. Improvement of the dissolution rate of silymarin by means of solid dispersions. *Chem Pharm Bull (Tokyo)* 2004;52:972-973.
43. Zhang P, Ye H, Min T, Zhang C. Water soluble poly (ethylene glycol) prodrug of silybin: design, synthesis, and characterization. *J Appl Polym Sci Symp* 2008;107:3230-3235.
44. Qiu MF, Jia W, Li SS, et al. A new silymarin preparation based on solid dispersion technique. *Adv Ther* 2005;22:595-600.
45. Nakhath PD, Naidu RA, Babla IB, et al. Design and evaluation of silymarin-HP-beta-CD solid dispersion tablets. *Indian J Pharm Sci* 2007;69:287-289.
46. Sun N, Wei X, Wu B, Chen J, Lu Y, Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. *Powder Technol* 2008;182:72-80.
47. Sun N, Zhang X, Lu Y, Wu W. *In vitro* evaluation and pharmacokinetics in dogs of solid dispersion pellets containing *Silybum marianum* extract prepared by fluid-bed coating. *Planta Med* 2008;74:126-132.
48. Kren V, Kubisch J, Sedmera P, et al. Glycosylation of silybin. *J Chem Soc* 1997;1:2467-2474.
49. Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. *Biochem Pharmacol* 1994;48:753-759.
50. Carducci R, Armellino MF, Volpe C, et al. Silibinin and acute poisoning with *Amanita phalloides*. *Minerva Anestesiol* 1996;62:187-193. [Article in Italian]
51. Pifferi G, Pace R, Conti M. Synthesis and antihepatotoxic activity of silybin 11-O-phosphate. *Farmaco* 1994;49:75-76.
52. Kosina P, Kren V, Gebhardt R, et al. Antioxidant properties of silybin glycosides. *Phytother Res* 2002;16:S33-S39.
53. Kosina P, Maurel P, Ulrichová J, Dvorák Z. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. *J Biochem Mol Toxicol* 2005;19:149-153.
54. Gazak R, Svobodová A, Psotová J, et al. Oxidised derivatives of silybin and their antiradical and antioxidant activity. *Bioorg Med Chem* 2004;12:5677-5687.
55. Dzubak P, Hajduch M, Gazak R, et al. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. *Bioorg Med Chem* 2006;14:3793-3810.

56. Zhang HL, Bai TC, Yan GB, Hu J. Solubility of silybin in aqueous poly(vinylpyrrolidone) solution. *Fluid Phase Equilib* 2005;238:186-192.
57. Bai TC, Yan GB, Zhang HL, Hu J. Solubility of silybin in aqueous dextran solutions. *J Chem Eng Data* 2005;50:1596-1601.
58. Bai TC, Yan GB, Hu J, et al. Solubility of silybin in aqueous poly(ethylene glycol) solution. *Int J Pharm* 2006;308:100-106.
59. Bai TC, Zhu JJ, Hu J, et al. Solubility of silybin in aqueous hydrochloric acid solution. *Fluid Phase Equilib* 2007;254:204-210.
60. Garg R, Gupta GD. Preparation and evaluation of gastroretentive floating tablets of silymarin. *Chem Pharm Bull (Tokyo)* 2009;57:545-549.
61. Savio D, Harrasser PC, Basso G. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. A bioavailability cross-over randomised study on silybin. *Arzneimittelforschung* 1998;48:1104-1106.
62. Debbage P. Targeted drugs and nanomedicine: present and future. *Curr Pharm Des* 2009;15:153-172.
63. Di Piero F, Callegari A, Carotenuto D, Tapia MM. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as galactagogue. *Acta Biomed* 2008;79:205-210.
64. Capasso R, Aviello G, Capasso F, et al. Silymarin BIO-C, an extract from *Silybum marianum* fruits, induces hyperprolactinemia in intact female rats. *Phytomedicine* 2009;16:839-844.
65. Zhang ZB, Shen ZG, Wang JX, et al. Micronization of silybin by the emulsion solvent diffusion method. *Int J Pharm* 2009;376:116-122.
66. Hung CF, Lin YK, Zhang LW, et al. Topical delivery of silymarin constituents via the skin route. *Acta Pharmacol Sin* 2010;31:118-126.
67. Lu C, Lu Y, Chen J, et al. Synchronized and sustained release of multiple components in silymarin from erodible glyceryl monostearate matrix system. *Eur J Pharm Biopharm* 2007;66:210-219.
68. Abrol S, Trehan A, Katare OP. Formulation, characterization, and *in vitro* evaluation of silymarin-loaded lipid microspheres. *Drug Deliv* 2004;11:185-191.
69. Abrol S, Trehan A, Katare OP. Comparative study of different silymarin formulations: formulation, characterisation and *in vitro/in vivo* evaluation. *Curr Drug Deliv* 2005;2:45-51.
70. <http://www.pharmainfo.net/nanocarriers> [Accessed: August 24, 2011]
71. El-Sherbiny IM, Abdel-Mogib M, Dawidar AM, et al. Biodegradable pH-responsive alginate-poly (lactic-co-glycolic acid) nano/micro hydrogel matrices for oral delivery of silymarin. *Carbohydr Polym* 2011;83:1345-1354.
72. Parveen R, Baboota S, Ali J, et al. Oil based nanocarrier for improved oral delivery of silymarin: *in vitro* and *in vivo* studies. *Int J Pharm* 2011;413:245-253.
73. He J, Feng JF, Zhang LL, et al. Freeze-drying of silymarin-loaded solid lipid nanoparticles (SM-SLN). *Zhongguo Zhong Yao Za Zhi* 2005;30:110-112. [Article in Chinese]
74. Jun H, Shixiang H, Weigen L, et al. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. *J Biomed Nanotechnol* 2007;3:195-202.
75. Xu XM, Li Q, Zhu Y, et al. Study on the preparation and bio-distribution of silybin lipid nanospheres. *Zhongguo Zhong Yao Za Zhi* 2005;30:1912-1914.
76. Gao HL, Pang ZQ, Fan L, et al. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: *in vitro* and *in vivo* evaluations. *Acta Pharmacol Sin* 2010;31:237-243.
77. Stevens AJ, Martin SW, Brennan BS, et al. Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. *Pharm Res* 1995;12:1987-1996.
78. Zhang JQ, Liu J, Li XL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silybinin. *Drug Deliv* 2007;14:381-387.
79. Jia LJ, Zhang DR, Li ZY, et al. Preparation and characterization of silybin-loaded nanostructured lipid carriers. *Drug Deliv* 2009 Nov 26 [Epub ahead of print]
80. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. *Adv Drug Deliv Rev* 2008;60:673-691.
81. Yuan Q, Li XR, Wang HJ, et al. The absorption kinetics of silymarin microemulsion in rat intestine. *Yao Xue Xue Bao* 2004;39:631-634. [Article in Chinese]
82. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. *Eur J Pharm Biopharm* 2006;63:288-294.
83. Liu L, Pang X, Zhang W, Wang S. Formulation design and *in vitro* evaluation of silymarin loaded self micro emulsifying drug delivery systems. *Asian J Pharm Sci* 2007;2:150-160.
84. Wu YP, Huo MR, Zhou JP. Preparation of silymarin-loaded amphiphilic chitosan micelle and its *in situ* absorption in rat intestine. *Yao Xue Xue Bao* 2009;44:651-657. [Article in Chinese]
85. Li X, Huang Y, Chen X, et al. Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin. *J Drug Target* 2009;17:739-750.